JAK1 (phospho-Tyr1022) Antibody
- Known as:
- JAK1 (phosphorilated-Tyr1022) Antibody
- Catalog number:
- abx000235
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- JAK1 (phospho-Tyr1022) Antibody
Related genes to: JAK1 (phospho-Tyr1022) Antibody
- Gene:
- JAK1 NIH gene
- Name:
- Janus kinase 1
- Previous symbol:
- JAK1B
- Synonyms:
- JAK1A, JTK3
- Chromosome:
- 1p31.3
- Locus Type:
- gene with protein product
- Date approved:
- 1992-04-16
- Date modifiied:
- 2016-10-05
Related products to: JAK1 (phospho-Tyr1022) Antibody
Related articles to: JAK1 (phospho-Tyr1022) Antibody
- We recently reported an immune profile that stratifies patients with axial spondyloarthritis based on clinical response to secukinumab. We now undertake an exploratory study on the secukinumab nonresponder patients to determine if immunologic changes occur during their initial secukinumab treatment that could determine their next biologic response. - Source: PubMed
Pacheco AddisonRemalante-Rayco PatriciaHaroon NigilPoddubnyy DenisInman Robert D - Whether prior biologic exposure attenuates the efficacy of upadacitinib (UPA), a selective JAK-1 inhibitor, in inflammatory bowel disease (IBD) remains unresolved. This systematic review addresses this question across the induction and maintenance phases of ulcerative colitis (UC) and Crohn's disease (CD). PubMed/MEDLINE, ScienceDirect, Scopus, and ClinicalTrials.gov were searched through from inception to January 2026 per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 (PROSPERO: CRD420261287632). Eligible studies were Phase 3 randomised controlled trials (RCTs) in moderate-to-severe UC or CD reporting subgroup data by biologic exposure status. Risk of bias was assessed with Cochrane RoB 2; narrative synthesis followed the Synthesis Without Meta-analysis (SWiM) framework. Three studies with six Phase 3 programs were included, all at low overall risk of bias. While therapeutic response rates were numerically lower in patients with prior biologic exposure, UPA demonstrated sustained therapeutic benefit observed across all subgroups. In Crohn's disease, stratified risk differences (RD) for clinical remission consistently favored UPA over placebo (RD range: 14.5-33.0 pp). While biologic-naive patients achieved numerically higher remission rates, biologic-experienced patients retained meaningful clinical and endoscopic benefit at one year. In ulcerative colitis, UPA demonstrated superior efficacy across all primary endpoints compared to placebo. Safety data revealed a dose-dependent increase in adverse events (e.g., herpes zoster, hepatic enzyme elevations) at 30 mg compared to 15 mg in the maintenance phase. UPA provides clinically meaningful remission in biologic-experienced IBD patients across both UC and CD. Although prior biologic exposure is associated with lower absolute remission rates, the sustained therapeutic benefit supports UPA as a viable salvage option. Further research with head-to-head trials is needed. - Source: PubMed
Publication date: 2026/07/28
Htun MayLilhori AnupriyaAlamgir MariamAl-Shemary MaremSriram RitvikAzeez NejmaRajbhandari PradeepMuratova AikenPatil SirilGodavarthy Prabhav KashyapMahmood AhmadKylanathan JannushTeli Advait - This study evaluated the ameliorative effects of Heterophyllin J, a cyclic peptide derived from , on lipopolysaccharide (LPS)-induced neuroinflammation in mice. Biochemical, and molecular analyses revealed that Heterophyllin J dose-dependently reduced hippocampal pro-inflammatory cytokines (IFN-γ, IL-1β, IL-6, TNF-α), suppressed oxidative stress (restoring glutathione and lowering malondialdehyde), and alleviated iron accumulation. Western blotting demonstrated Heterophyllin J downregulated NLRP3, Caspase1, and TLR4/NF-κB pathway proteins (COX-2, iNOS, Myd88) while enhancing antioxidant markers (Nrf2, HO-1, NQO1) via Keap1/Nrf2 activation. Heterophyllin J also modulated JAK/STAT signaling, restoring JAK1/2 phosphorylation and reducing STAT1/3 activation, thereby attenuating apoptosis (lower Bax, cleaved caspase-3; higher Bcl-2) and ferroptosis (upregulating GPX4, PCBP1, SLC40A1). These findings highlight Heterophyllin J's multimodal mechanism: regulating TLR4-driven inflammation, rebalancing iron metabolism, and activating antioxidant pathways to counteract neuroinflammation. The results position Heterophyllin J as a promising therapeutic candidate for neurodegenerative diseases linked to neuroinflammatory and oxidative stress pathways. - Source: PubMed
Publication date: 2026/06/27
Li BoShi XueyingChen ErhuaChen Xianwen - Idiopathic subglottic stenosis (iSGS) is a fibroinflammatory airway disease causing airway narrowing. Standard treatments are surgical and range from endoscopic procedures to open tracheal resections; there are no adjuvant medical therapies to reduce disease burden. In similar fibroinflammatory diseases such as rheumatoid arthritis (RA), Janus kinase (JAK) inhibitors show great promise in reducing disease severity and recurrence. Therefore, this study sought to identify the potential impact of JAK inhibitors (JAKi) as a novel treatment in iSGS. - Source: PubMed
Publication date: 2026/08/27
Larkin Riley MLina IoanKostas JuliannaChristmann CarolineByram KevinGelbard Alexander - Diabetic Kidney Disease (DKD) is a prevalent complication of uncontrolled hyperglycemia that imposes a considerable burden on the health system due to the need for renal replacement therapy in the long term. Therefore, early diagnosis and prevention of renal damage in diabetic patients is critical. In the present study, we investigated the expression level of Janus kinase (Jak) 1, 2, and 3 genes, which play a role in the signal transduction of inflammatory cytokines and growth factors, for therapeutic or diagnostic purposes. - Source: PubMed
Publication date: 2026/07/29
Freidoon MahboobehSayadi NaghmehAssadiasl SaraKazemzadehghadim HadiSoleimanifar NarjesSadr MaryamMojtahedi HaniehAhmadi MaryamNicknam Mohammad Hossein